Topical antifungal treatment

Details Topical antifungal treatment Topical antifungal treatment

2008-05-20

2008-05-20

Sheikh, Humera N (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Wearing apparel, fabric, or cloth

C514S725000

Reexamination Certificate

active

07374772

ABSTRACT:
The present invention is a topical skin preparation for treatment of fungal infections of the skin and nails. The preparation comprises triacetin in combination with an antifungal agent. In a preferred form, the preparation further comprises, a fatty acid source such as a fish oil. In a preferred embodiment, cod liver oil and tolnaftate are used in combination with triacetin. The concentrations of these constituents are 96.0-99.0% concentration triacetin, 0.5-3.0% concentration tolnaftate and 0.5-1.0% concentration cod liver oil, in one preferred embodiment. Other compounds, such as ethyl alcohol, amino acids such as n-acetylcysteine, and herbal additives may also be added to the preparation. Further, other antifungal agents such as nystatin, clortimazole, econazole, ketoconazole, miconazole, solconazole, oxiconizole, naftifine, terbinafine, and butenafine, for example, may be substituted for the antifungal agent tolnaftate. The preparation of the present invention is effective in treating immune compromised patients and those with diabetes, as well as relatively healthy persons.

REFERENCES:
patent: 4263313 (1981-04-01), Eckert et al.
patent: 4323558 (1982-04-01), Nelson
patent: 4895727 (1990-01-01), Allen
patent: 5209932 (1993-05-01), Nichols
patent: 5482965 (1996-01-01), Rajadhyaksha
patent: 5661170 (1997-08-01), Chodosh
patent: 5846971 (1998-12-01), Sangekar et al.
patent: 6011067 (2000-01-01), Hersh
patent: 6017520 (2000-01-01), Synodis et al.
patent: 6017900 (2000-01-01), Falk et al.
patent: 6080744 (2000-06-01), Ayon-Covarrubias
patent: 6096338 (2000-08-01), Lacy et al.
patent: 6159977 (2000-12-01), Reeves
patent: 6224887 (2001-05-01), Samour et al.
patent: 6231865 (2001-05-01), Hsu et al.
patent: 6231875 (2001-05-01), Sun et al.
patent: 6267985 (2001-07-01), Chen et al.
patent: 6268355 (2001-07-01), Mizobuchi et al.
patent: 6299900 (2001-10-01), Reed et al.
patent: 6306843 (2001-10-01), Burghart et al.
patent: 6492395 (2002-12-01), Scheiwe et al.
patent: 6524593 (2003-02-01), Yu et al.
patent: 6541517 (2003-04-01), Murphy et al.
patent: 6762158 (2004-07-01), Lukenbach et al.
Jorge E. Arrese, Claudine Pierard-Franchimont and Gerald E. Pierard, “A Plea to Bridge the Gap Between Antifungals and the Management of Onychomycosis” Am J Clin Derm 2001.
AHFS Drug Information 2002; 3361-3401.
M.S.P. Sastry, P. Rama Rao, and P.V. Diwan, “Percutaneous Absorption of Naproxen From Different Ointment Bases in Rats.” Indian Journal of Pharmacology 1995; 27:130-132.
AHFS Drug Information 2002; 3402-3043.
Jacques F.G.M. Meis and Paul E. Verweij, “Current Management of Fungal Infections”, Drugs 2001:61 Suppl. 1:13-25 (Adis International Limited).
Vijay N. Joish and Edward P. Armstrong, “Which Antifungal Agent for Onychomycosis”, PharmacoEconomics 2001; 19(10): 983-1002; (Adis International Limited).
Jeffrey M. Robbins, DPM, “Recognizing, treating, and preventing common foot problems”; Cleveland Clinic Journal of Medicine, 67(1), Jan. 2000.
James W. Shaw, Vijay N. Joish and Stephen Joel Coons, “Onychomycosis Health-Related Quality of Life Considerations”, PharmacoEconomics 2002:20(1): 23-36 (Adis International Limited).
Daniele Debruyne and Antoine Coquerel, “Pharmacokinetics of Antifungal Agents in Onychomycoses”, Clin Pharmacokinet 2001; 40(6): 441-472 (Adis International Limited).
R.J. Hay “The future of onychomcosis therapy may involve a combination of approaches”, British Journal of Dermatology (2001) 145, (Suppl. 60), 3-8.
Medlineplus Drug Information; Internet; “Tolnafte”.
Fay Crawford,PhD; Philip Young, PhD, Christine Godfrey, BA; Sally E.M. Bell-Syer, MSc; Rachel Hart, BSc, Elizabeth Brunt, BMBS; Ian Russel, PhD, “Oral Treatments for Toenail Onychomycosis”; Arch Dermatology vol. 138 (Jun. 2002), p. 811-816.
Kenneth James Meehan, PA-C; Charles Miller, MD., “The clinical challenge of onychomycosis”, JAAPA 14(4), Apr. 2001; p. 43-50.
Catherine M. Tom and Michael P. Kane, “Management of toenail onychomycosis”, American Society of Health-System Pharmacists, vol. 56, p. 865-869; (May 1, 1999).
Aditya Kumar Gupta and Stephanie Humke, “The prevalence and management of onychomycosis in diabetic patients”, EJD 5(10):379-384 (Jul.-Aug. 2000).
Phillip Rodgers, M.D.and Mary Bassler, M.D., “Treating Onychomycosis” American Family Physician 63(4); p. 663-672 (Feb. 15, 2001).
Aditya K. Gupta and Neil H. Shear, “A Risk-Benefit Assessment of the Newer Oral Antifungal Agents Used to Treat Onychomycosis”, Drug Safety Jan. 2000: 22(1); 33-52 (Adis International Limited).
E.G.V: Evans, “The rational for combination therapy”, British Journal Of Dermatology (2001) 145. (Suppl.60). 9-13.
Handbook Of Nonprescription Dugs, 11th Edition; American Pharmaceutical Association (p. 558-562).
The Merck Manual, Sixteenth Edition (p. 2419-2422).
Philip Fleckman, MD, Emily F. Omura, MD., “Histopathology of the Nail”, Advances In Dermatology, vol. 17, p. 385-406, 2001.
Mary P. English, “Nails and Fungi”, British Journal of Dermatology (1976), 94, p. 697-701.
Nardo Zaias, MD, “Onychomycosis”, Arch Dermatology, vol. 105, p. 263-274 (Feb. 1972).
Rudolf L. Baer, M.D., Stanley A. Rosenthal, Ph.D., “Experimental Investigations on Mechanism Producing Acute Dermatophytosis of Feet”, J.A.M.A 160(3) p. 184-190, (Jan. 21, 1956).
Martindale The Extra Phamacopoeia, Thirtieth Edition; p. 332, The Pharmaceutical Press 1993.
The Merck Index, An Encyclopedia of Chemicals, Drugs, and Biologicals, Eleventh Edition; “Triacetin”, Merck & Co., Inc. 1989.
The Merck Index, An Encyclopedia of Chemicals, Drugs, and Biologicals, Eleventh Edition; “Tolnaftate”; Merck & Co., Inc. 1989.
“Fungal Infections of Fingernails and Toenails”, American Academy of Family Physicians, Information from Your Family Doctor (Feb. 2001).

Affiliated with

Also associated with

Rating

Topical antifungal treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Topical antifungal treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Topical antifungal treatment will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2813606